SCHEMBL6715748

SCHEMBL6715748

COc1cc(Cl)c(-c2ccc3c(c2)cc2n3CCNCC2)c(Cl)c1

nearest known ligand 0.54

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
HTR2A P28223 12/20 0.54
HTR2C P28335 12/20 0.54
ADRB1 P08588 2/20 0.42
HTR2B P41595 1/20 0.38
TGFBR1 P36897 1/20 0.35
HTR1A P08908 3/20 0.35
HTR3A P46098 1/20 0.35
HTR1D P28221 1/20 0.34
HTR1B P28222 1/20 0.34
HTR7 P34969 1/20 0.33
KDM4E B2RXH2 1/20 0.33
ALDH1A1 P00352 1/20 0.33
POLB P06746 1/20 0.33
GAA P10253 1/20 0.33
UBE2N P61088 1/20 0.33
KMT2A Q03164 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6719038 0.92 HTR2A (0.53) HTR2AHTR2CADRB1HTR2BTGFBR1
SCHEMBL6712442 0.88 HTR2A (0.57) HTR2AHTR2CADRB1
SCHEMBL6712409 0.88 HTR2A (0.57) HTR2AHTR2CADRB1HTR1AHTR3A
SCHEMBL6718518 0.85 HTR2A (0.62) HTR2AHTR2CADRB1HTR2BTGFBR1
SCHEMBL6711279 0.84 HTR2A (0.59) HTR2AHTR2CADRB1HTR2BHTR1A
SCHEMBL26838992 0.82 HTR2A (0.77) HTR2AHTR2CADRB1HTR1AHTR3A
SCHEMBL6711445 0.82 HTR2A (0.50) HTR2AHTR2CADRB1TGFBR1HTR1A
SCHEMBL6716207 0.80 HTR2A (0.58) HTR2AHTR2CADRB1HTR1AHTR3A
SCHEMBL6718656 0.80 HTR2A (0.58) HTR2AHTR2CADRB1HTR1AHTR3A
SCHEMBL6715974 0.79 HTR2C (0.56) HTR2AHTR2CADRB1HTR2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040209870-A1 Novel 2,3,4,5-tetrahydro-1H-[1,4]diazepino[1,7-a]indole compounds ENNIS MICHAEL DALTON (US) 2004-10-21 US claimed
US-6734301-B2 5-HT LIGANDS USED TO TREAT CENTRAL NERVOUS SYSTEM DISORDERS PHARMACIA & UPJOHN COMPANY 2004-05-11 US claimed
EP-1328525-A2 2,3,4,5-TETRAHYDRO-1H-[1,4]DIAZEPINO[1,7-A]INDOLE COMPOUNDS PHARMACIA & UPJOHN COMPANY (US) 2003-07-23 EP claimed
US-20020002161-A1 Novel 2,3,4,5-tetrahydro-1H-[1,4]diazepino[1,7-a]indole compounds PHARMACIA & UPJOHN COMPANY 2002-01-03 US claimed
WO-2001072752-A2 2,3,4,5-TETRAHYDRO-1H-[1,4]DIAZEPINO[1,7-a]INDOLE COMPOUNDS PHARMACIA & UPJOHN COMPANY (US) 2001-10-04 WO claimed
US-20040209870-A1 Novel 2,3,4,5-tetrahydro-1H-[1,4]diazepino[1,7-a]indole compounds ENNIS MICHAEL DALTON (US) 2004-10-21 US disclosed
US-6734301-B2 5-HT LIGANDS USED TO TREAT CENTRAL NERVOUS SYSTEM DISORDERS PHARMACIA & UPJOHN COMPANY 2004-05-11 US disclosed
US-20020002161-A1 Novel 2,3,4,5-tetrahydro-1H-[1,4]diazepino[1,7-a]indole compounds PHARMACIA & UPJOHN COMPANY 2002-01-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020002161-A1 Novel 2,3,4,5-tetrahydro-1H-[1,4]diazepino[1,7-a]indole compounds HTR1D, HTR1A, HTR1E HTR2A 18/4885HTR2C 7/4885ADRB1 30/4885
US-20040209870-A1 Novel 2,3,4,5-tetrahydro-1H-[1,4]diazepino[1,7-a]indole compounds HCRTR2, NR2C2, RCOR3 HTR2A 1403/4885HTR2C 553/4885ADRB1 187/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.